Certolizumab pegol and its role in pregnancy-age hidradenitis suppurativa

Int J Dermatol. 2022 May;61(5):e182-e184. doi: 10.1111/ijd.15742. Epub 2021 Jul 16.

Authors

Federica Repetto¹, Lorenza Burzi¹, Alice Ramondetta¹, Giulia Rozzo¹, Matteo Licciardello¹, Simone Ribero¹, Pietro Quaglino¹, Paolo Dapavo¹

Affiliation

¹ Department of Medical Sciences, Dermatology Clinic, University of Turin, Turin, Italy.

PMID: 34270087
DOI: 10.1111/ijd.15742

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Certolizumab Pegol / therapeutic use
Female
Hidradenitis Suppurativa* / drug therapy
Humans
Maternal Age
Pregnancy
Tumor Necrosis Factor-alpha

Substances

Antibodies, Monoclonal, Humanized
Tumor Necrosis Factor-alpha
Certolizumab Pegol